Sunlight Financial to Participate in Cowen Investor Conference
NEW YORK & CHARLOTTE, N.C.–(BUSINESS WIRE)–Sunlight Financial Holdings Inc. (“Sunlight Financial”, “Sunlight” or the “Company”)…
Year: 2022
Sharp NEC Display Solutions Debuts NaViSense Computer Vision at InfoComm 2022
The groundbreaking solution will lead to sharper audience insights and improved customer experience in a…
Quantropi Unveils New “Digital QKD” Quantum-Secure Product at RSA Conference 2022
Canadian quantum cybersecurity innovator establishes new world records for Quantum Key Distribution OTTAWA, June 07,…
American Elm Distribution Partners, LLC Rebrands with a New Logo, Website and Expansion of Services
As part of this rebrand, American Elm has expanded the services it offers to include…
WallStreetBets and Osprey Funds present: FOMO Casino Night in Austin
Osprey Funds following the launch of their Osprey Polkadot Trust join the Founder of WallStreetBets…
Neustar Security Services wins 2022 Fortress Cyber Security Award
UltraDDoS Protect recognized as leading solution in Incident Response category STERLING, Va.–(BUSINESS WIRE)–Neustar Security Services,…
Symetra Names Morgan State University National HBCU Partner
Symetra funding to provide scholarships and wraparound support to 25 Black students by 2025 BELLEVUE,…
CA Ventures Chooses PERQ as Automation Platform for Managing the Renters’ Experience
3-Month Pilot Shows Improved Conversions and Cost Savings Opportunity INDIANAPOLIS–(BUSINESS WIRE)–#multifamilyinnovation–Today PERQ announced that CA…
medZERO Adds Another FinTECH Award at Meta Lab Challenge
CHARLOTTE, N.C.–(BUSINESS WIRE)–#benefits–medZERO, with its innovative healthcare financing platform, was one of five companies selected…
Four UBS advisors in the Midwest Private Wealth Management market named to the Forbes/SHOOK Best-in-State Wealth Advisors list
DENVER–(BUSINESS WIRE)–UBS Private Wealth Management announced today that advisors Jonathan Beukelman, Michael Chudd, Mark Geist,…
Wells Fargo Names Amy Bonitatibus as Chief Communications and Brand Officer
Bonitatibus joins Wells Fargo from Chase where she served as Chief Communications Officer SAN FRANCISCO–(BUSINESS…
Kira Learning Announces $6 Million Seed Round Financing Led by NEA and Dr. Andrew Ng’s AI Fund
The Company will deploy the funds to build the solution of choice for K-12 schools…
Unifi Protocol Approved for Massive Upgrade to $11M Multichain Infrastructure in Landmark DAO Proposal
AUSTIN, Texas–(BUSINESS WIRE)–$UNFI #DAO–Unifi Protocol DAO is set to launch a massive upgrade to their…
Snowden Lane Partners, Estancia Capital Partners Secure Extended $50 Million Credit Facility
The New Loan, Enabled by Estancia Capital Partners, Will Allow Snowden Lane to Execute its…
PIXM Named Winner of the Coveted Global InfoSec Awards during RSA Conference 2022
PIXM Wins Cutting Edge Cybersecurity Artificial Intelligence and Next Gen Cybersecurity Artificial Intelligence in 10th…
Mastercard Commits to Delivering Economic Empowerment Tools and Resources to More than One Million Women in Guatemala, El Salvador, and Honduras
Company to empower women and girls in Northern Central America with access to training, capital,…
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1…
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE…
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8
Saint–Herblain (France), June 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty…
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate…